An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) is a PHASE3 clinical asset sponsored by Ionis Pharmaceuticals, Inc. in Hereditary Angioedema. SEO and diligence focus: Donidalorsen, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.